Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
基本信息
- 批准号:8450787
- 负责人:
- 金额:$ 59.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-04-01 至 2016-03-31
- 项目状态:已结题
- 来源:
- 关键词:AddressAdverse effectsBasic ScienceCancer ModelCancer PatientClinicClinicalClinical TrialsComplexContrast MediaDataDiagnosticDisease ProgressionDistalDosage FormsDoseDrug KineticsEpithelial ovarian cancerFolateGadoliniumGoalsHumanImageIn VitroInvestigationKnowledgeLaboratoriesLightLinkLocalized DiseaseMagnetic Resonance ImagingMalignant NeoplasmsMalignant neoplasm of ovaryMedicineModalityModelingMorphologyMulti-Drug ResistanceMusNanotechnologyNeoplasm MetastasisNewly DiagnosedNormal tissue morphologyOutcomePaclitaxelPharmaceutical PreparationsPhenotypePlasmaPolysorbate 80RattusRecurrenceRecurrent Malignant NeoplasmRecurrent diseaseRecurrent tumorRefractoryRegimenResearch PersonnelSafetySolutionsSystemTechnologyTherapeutic AgentsTimeTissuesToxic effectTransgenic MiceTranslatingTreatment EfficacyTreatment ProtocolsValidationXenograft procedurebasecancer therapychemotherapeutic agentcombatcytotoxicitydesigndocetaxeleffective therapyexhaustexperiencegadolinium oxidehuman FOLR1 proteinimprovedin vivoinnovationinsightintraperitonealmalignant breast neoplasmmanmortalitymouse modelnanocarriernanoemulsionnanomedicinenovelovarian neoplasmpreclinical studyresidencetumoruptake
项目摘要
DESCRIPTION (provided by applicant): During treatment recurrent cancers build up multidrug resistance to conventional and novel chemotherapeutic agents representing a formidable challenge in clinical cancer therapy, especially for the effective treatment of gynecological malignancies. This R01 proposal describes a targeted-, combination imaging agent and therapeutic nanoemulsion, designated NMI-500, designed to provide timely diagnostic information on where the co-deliver treatment is accumulating and provide clinicians the quantitative insight to adjust treatment schedules in light of this new information. A team of investigators from two commercial and two academic organizations will collaborate to develop this clinically translatable strategy, initially addressing recurrent multidrug resistant phenotype. NMI-500 uses folate to specifically target docetaxel (DTX), and gadolinium (Gd) an MR imaging agent to localized disease as well as distal metastases. NMI-500's targeting moiety folate is known to improve uptake by tumors expressing folate receptor alpha (FR-a). FR- a, largely absent from normal tissue, has been shown to be over expressed on >80% of recurring ovarian tumors. In breast cancer high FR-an expression has been linked to poor clinical outcomes. The imaging component of NMI-500 will be achieved with the MRI contrast agent Gd, which has been shown to enhance contrast efficiency when conjugated to a nanoemulsion.1 Specific aims will assess and validate the imaging, targeting, efficacy and pharmacokinetics of the combination imaging/chemotherapeutic product, NMI-500.
描述(由申请人提供):在治疗期间,复发性癌症对传统和新型化疗药物产生多药耐药性,这对临床癌症治疗,特别是对妇科恶性肿瘤的有效治疗提出了巨大的挑战。该 R01 提案描述了一种靶向组合显像剂和治疗性纳米乳剂,命名为 NMI-500,旨在提供有关共同提供治疗累积情况的及时诊断信息,并为临床医生提供定量见解,以根据这一新的情况调整治疗计划。信息。来自两个商业组织和两个学术组织的研究人员团队将合作开发这种可临床转化的策略,最初解决复发性多药耐药表型。 NMI-500 使用叶酸专门靶向多西紫杉醇 (DTX),并使用钆 (Gd) 一种 MR 成像剂来靶向局部疾病和远端转移。 NMI-500 的靶向部分叶酸已知可改善表达叶酸受体 α (FR-a) 的肿瘤的摄取。 FR-a 在正常组织中基本上不存在,已被证明在超过 80% 的复发性卵巢肿瘤中过度表达。在乳腺癌中,FR-an 高表达与不良临床结果相关。 NMI-500 的成像组件将通过 MRI 造影剂 Gd 来实现,该造影剂已被证明与纳米乳剂结合时可提高造影效率。1 具体目标将评估和验证组合成像的成像、靶向、功效和药代动力学/化疗产品,NMI-500。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Mansoor M Amiji其他文献
Mansoor M Amiji的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Mansoor M Amiji', 18)}}的其他基金
TGX-1214 - Combination Strategy for the Treatment of Advanced Pancreatic Cancer
TGX-1214 - 治疗晚期胰腺癌的联合策略
- 批准号:
10607971 - 财政年份:2023
- 资助金额:
$ 59.65万 - 项目类别:
Intranasal gene delivery for Alzheimer’s disease
鼻内基因递送治疗阿尔茨海默病
- 批准号:
10308277 - 财政年份:2021
- 资助金额:
$ 59.65万 - 项目类别:
Integrated Nano-Therapeutics to Overcome Tumor Plasticity and Resistance
综合纳米疗法克服肿瘤可塑性和耐药性
- 批准号:
9165227 - 财政年份:2017
- 资助金额:
$ 59.65万 - 项目类别:
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
用 MicroRNA 纳米载体重编程 PDAC 中的肿瘤相关巨噬细胞
- 批准号:
9382014 - 财政年份:2017
- 资助金额:
$ 59.65万 - 项目类别:
Reprogramming Tumor-Associated Macrophages in PDAC with MicroRNA Nano-Vectors
用 MicroRNA 纳米载体重编程 PDAC 中的肿瘤相关巨噬细胞
- 批准号:
9517784 - 财政年份:2017
- 资助金额:
$ 59.65万 - 项目类别:
Oral Gene Delivery to Improve Iron Overload Disorders
口服基因递送改善铁过载疾病
- 批准号:
9173116 - 财政年份:2016
- 资助金额:
$ 59.65万 - 项目类别:
Targeted Platinates/siRNA Combination Therapy for Resistant Lung Cancer
靶向铂酸盐/siRNA 联合治疗耐药肺癌
- 批准号:
8688558 - 财政年份:2014
- 资助金额:
$ 59.65万 - 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:
8633430 - 财政年份:2011
- 资助金额:
$ 59.65万 - 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:
8090583 - 财政年份:2011
- 资助金额:
$ 59.65万 - 项目类别:
Integrated Image-Guided Targeted Therapy for Refractory Ovarian Cancer
难治性卵巢癌的综合影像引导靶向治疗
- 批准号:
8248798 - 财政年份:2011
- 资助金额:
$ 59.65万 - 项目类别:
相似国自然基金
基于真实世界医疗大数据的中西药联用严重不良反应监测与评价关键方法研究
- 批准号:82274368
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
OR10G7错义突变激活NLRP3炎症小体致伊马替尼严重皮肤不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于隐狄利克雷分配模型的心血管系统药物不良反应主动监测研究
- 批准号:82273739
- 批准年份:2022
- 资助金额:52 万元
- 项目类别:面上项目
基于真实世界数据的创新药品上市后严重罕见不良反应评价关键方法研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
D.formicigenerans菌通过调控FoxP3-Treg影响PD-1抑制剂所致免疫相关不良反应的机制研究
- 批准号:
- 批准年份:2022
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Improving Information Sharing Between Family Caregivers and Home Care Aides Caring for Persons Living with ADRD
改善照顾 ADRD 患者的家庭护理人员和家庭护理助理之间的信息共享
- 批准号:
10571144 - 财政年份:2023
- 资助金额:
$ 59.65万 - 项目类别:
Food and Non-Food Self-Regulation in Children's Obesity Risk: A Biopsychosocial Perspective
儿童肥胖风险中的食品和非食品自我调节:生物心理社会视角
- 批准号:
10561810 - 财政年份:2023
- 资助金额:
$ 59.65万 - 项目类别:
Music mechanisms and technologies network: Integrative models to address pain through music
音乐机制和技术网络:通过音乐解决疼痛的综合模型
- 批准号:
10765327 - 财政年份:2023
- 资助金额:
$ 59.65万 - 项目类别:
Efficacy and safety of nanoparticle mediated placental gene therapy in nonhuman primates
纳米颗粒介导的胎盘基因治疗对非人灵长类动物的功效和安全性
- 批准号:
10752759 - 财政年份:2023
- 资助金额:
$ 59.65万 - 项目类别:
Defining kinase interaction pathways to enhance anti-cancer efficacy and minimize associated morbidities of kinase inhibitor drugs.
定义激酶相互作用途径,以增强抗癌功效并最大限度地减少激酶抑制剂药物的相关发病率。
- 批准号:
10644554 - 财政年份:2023
- 资助金额:
$ 59.65万 - 项目类别: